Literature DB >> 9657222

Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction.

H Lindenblatt1, E Krämer, P Holzmann-Erens, E Gouzoulis-Mayfrank, K A Kovar.   

Abstract

Two modifications of the HPLC-ED method with respect to extraction procedure used have been developed for psilocin, the active metabolite of psilocybin, in human plasma using either liquid-liquid extraction (LLE) or automated on-line solid-phase extraction (on-line SPE). Each type of the sample preparation required a different HPLC system followed by electrochemical detection at 650 to 675 mV. The limit of quantitation of both modifications was 10 ng/ml psilocin. There was no significant difference observable between the LLE and the on-line SPE in terms of method standard deviation (LLE 1.82%, on-line SPE 1.13%) and the analytical results. However, the advantages of on-line SPE in addition to different selectivity were less manual effort, smaller plasma volumes of 400 microl (LLE 2 ml) and a recovery of psilocin in human plasma of nearly 100% (LLE 88%). In contrast to a previous procedure both methods were rapid, simple and reliable and yielded high plasma recoveries. They were used successfully in the quantitation of psilocin in plasma samples obtained from healthy volunteers after p.o. administration of 0.2 mg psilocybin per kg body mass. Plasma concentration curves and pharmacokinetic parameters were calculated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657222     DOI: 10.1016/s0378-4347(98)00067-x

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  9 in total

1.  A validated method for quantitation of psilocin in plasma by LC-MS/MS and study of stability.

Authors:  Rafaela Martin; Jennifer Schürenkamp; Heidi Pfeiffer; Helga Köhler
Journal:  Int J Legal Med       Date:  2011-12-03       Impact factor: 2.686

2.  Development of a psilocin immunoassay for serum and blood samples.

Authors:  C Albers; H Köhler; M Lehr; B Brinkmann; J Beike
Journal:  Int J Legal Med       Date:  2004-08-03       Impact factor: 2.686

3.  Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.

Authors:  Matthew W Johnson; R Andrew Sewell; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2011-11-29       Impact factor: 4.492

4.  Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.

Authors:  Felix Hasler; Ulrike Grimberg; Marco A Benz; Theo Huber; Franz X Vollenweider
Journal:  Psychopharmacology (Berl)       Date:  2003-11-13       Impact factor: 4.530

5.  Research on acute toxicity and the behavioral effects of methanolic extract from psilocybin mushrooms and psilocin in mice.

Authors:  Olga Zhuk; Izabela Jasicka-Misiak; Anna Poliwoda; Anastasia Kazakova; Vladlena V Godovan; Marek Halama; Piotr P Wieczorek
Journal:  Toxins (Basel)       Date:  2015-03-27       Impact factor: 4.546

Review 6.  Recreational use, analysis and toxicity of tryptamines.

Authors:  Roberta Tittarelli; Giulio Mannocchi; Flaminia Pantano; Francesco Saverio Romolo
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

7.  Dose-response relationships of psilocybin-induced subjective experiences in humans.

Authors:  Tim Hirschfeld; Timo T Schmidt
Journal:  J Psychopharmacol       Date:  2021-03-04       Impact factor: 4.153

Review 8.  Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?

Authors:  Maurizio Coppola; Francesco Bevione; Raffaella Mondola
Journal:  J Xenobiot       Date:  2022-02-07

9.  Direct Analysis of Psilocin and Muscimol in Urine Samples Using Single Drop Microextraction Technique In-Line with Capillary Electrophoresis.

Authors:  Anna Poliwoda; Katarzyna Zielińska; Piotr P Wieczorek
Journal:  Molecules       Date:  2020-03-29       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.